2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1352

Predictors of Mortality in Rheumatic Disease Patients with CMV Infection

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1679

Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1266

Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated By an Aggressive Treat-to-Target Regimen

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1882

Predictors of Response to Methotrexate in Patients with Eosinophilic Fasciitis (Shulman’s Disease)

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1533

Pregnancy Outcomes in Women with Rheumatoid Arthritis : A Systematic Review and Meta-Analyses

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1400

Preliminary Validation of the Turkish Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY) in a Single Center

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1228

Prescribing for Children with Rheumatologic Disease: Differences Between Pediatric and Adult Rheumatologists

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1942

Presentation and Clinical Features of ANCA-Associated Vasculitis in US African Americans: Experience from a Single Center

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1949

Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1785

Prevalence and Associated Factors of Low Bone Mass in Adults with Systemic Lupus Erythmatosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1508

Prevalence and Clinical Characteristics of Rheumatoid Arthritis in Sickle Cell Patients: A Cross-Sectional Analysis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1537

Prevalence and Impact of Inflammatory Multimorbid Conditions on Trajectories of Disease Activity in the First Year of Follow-up in a Multi-Center Era Cohort

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1813

Prevalence and Incidence of Systemic Lupus Erythematosus in Tucuman -Argentina

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1876

Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1893

Prevalence of Antiphospholipid Antibodies in Systemic Sclerosis: A Systematic Review and Meta-Analysis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].